Cargando…
Corrigendum to: Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013629/ https://www.ncbi.nlm.nih.gov/pubmed/36749184 http://dx.doi.org/10.1093/neuonc/noad026 |
Ejemplares similares
-
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C
por: Mishima, Kazuhiko, et al.
Publicado: (2022) -
Corrigendum to: Prospective evaluation of high‐dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function
Publicado: (2022) -
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020) -
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
por: Wakabayashi, Toshihiko, et al.
Publicado: (2018) -
A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)
por: Arakawa, Yoshiki, et al.
Publicado: (2021)